期刊文献+

生物等效性试验质量管理的思考和实践 被引量:2

Ponderation and practice on the quality management of bioequivalence study
下载PDF
导出
摘要 生物等效性试验是评价制剂质量的重要指标,有效的质量管理策略和措施是生物等效性试验设计和实施的重要考量。在某三级甲等医院生物等效性(预)试验质量管理中,常见以下问题:受试者不能完全依从方案、试验药物管理记录不完善、生物样本采集与管理违背方案或记录不详细、仪器设备管理不规范或记录不完整、试验数据记录不准确或逻辑不清。加强研究团队成员的沟通协作、完善制度文件体系建设、充分准备试验物资、细化试验操作程序并详细记录数据,有助于减少质量问题,提高试验实施质量,保证临床试验数据真实、可靠。 Bioequivalence study is an important index to evaluate the quality of preparations,and effective strategies and measures of quality management are important considerations in the design and implementation of bioequivalence studies.The problems frequently arising in the quality management of bioequivalence(pre)studies in grade 3A hospital:the subjects cannot fully comply with the protocol;the test drug management records are incomplete;the collection and management of biological samples violate the protocol or the records are not detailed;the management of instruments and equipment is not standardized or the records are incomplete;the records of test data are inaccurate or unclear.Strengthening the communication and cooperation among the members of the research team,perfecting the system construction of institutional documents,fully preparing test materials,refining test operation procedures and recording data in detail help to reduce quality problems,improve the quality of implementation of bioequivalence studies,and ensure the authenticity and reliability of the data.
作者 刘琳 何艳 曾忱 曾艳 陈璐 周岩 熊芸 LIU Lin;HE Yan;ZENG Chen;ZENG Yan;CHEN Lu;ZHOU Yan;XIONG Yun(Office of Drug Clinical Trial Institution,the Affiliated Hospital of Guizhou Medical University,Guizhou,Guiyang 550002,China)
出处 《中国医药科学》 2021年第2期216-218,共3页 China Medicine And Pharmacy
基金 贵州省贵阳市科技局科技计划项目(筑科合同[20151001]社80号)。
关键词 生物等效性试验 质量管理 临床研究机构 策略 Bioequivalence study Quality management Clinical research in stitution Strategy
  • 相关文献

参考文献14

二级参考文献93

  • 1宋敏,杭太俊,沈建平,陶萍,张银娣,张正行.HPLC-MS法研究氯雷他定片人体相对生物利用度及药代动力学[J].药物分析杂志,2004,24(4):374-377. 被引量:5
  • 2马涛,李见春,蒋志文.氯雷他定口腔崩解片人体药动学及生物等效性评价[J].蚌埠医学院学报,2007,32(1):84-87. 被引量:2
  • 3钟大放.以加权最小二乘法建立生物分析标准曲线的若干问题[J].药物分析杂志,1996,16(5):343-346. 被引量:579
  • 4ZHANG YF, CHEN XY, ZHONG DF, et al. Pharmacokinetics of loratadine and its active metabolite descarboethoxyloratadine in healthy Chinese subjects [ J ]. Acta Pharmacol Sin, 2003,24 (7) : 715 -718.
  • 5YUMIBE N, HUIE K, CHEN KJ, et al. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine, Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6 [ J ]. Biochem Pharmacol, 1996,51 ( 2 ) :165 -172.
  • 6王苏英,施建英,叶小丽,吴素香.影响血压测量的有关因素[J].中华护理杂志,2007,42(9):839-841. 被引量:30
  • 7CFDA.化学药物制剂人体生物利用度和生物等效性研究技术指导原则[EB/OL].(2007-08-23)[2008-04-29].http://www.cde.org.cn/zdyz.do?method=largePage&id:2066.
  • 8EMA. Guideline on bioanalytical method validation [EB/OL]. (2011-07 -21 ) [2012 -10-22]. http ://www.ema.europa.eu/docs/ en_GB/document_library/Scientific_guideline/2011/08/WC50010 9686.pdf.
  • 9FDA. Guidance for industry: bioanalytical method validation [EB/ OL]. (2001 -05 ) [2011 -03 - 10]. http ://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guid ances/ucm 070107.pdf.
  • 10CFDA.化学药物非临床药代动力学研究技术指导原则[EB/OL].(2007-08-23)[2008-04-29].http://www.cde.org.cn/zdyz.do?method=largePage&id=2056.

共引文献88

同被引文献14

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部